Gilead, Merck jointly developing new HIV drug

Monday, 15. March 2021 11:26

Gilead Sciences and Merck & Co. announced on Monday the two drugmakers are teaming up on the development of a new long-acting HIV therapy.

The cocktail would be a combination of the companies' respective experimental drugs, lenacapavir and Islatravir, which the pair hopes could lead to a new therapy that HIV patients will take every several months.

“It’s a big deal for people living with HIV. It has the potential to bring a long-acting medicine as much as two years earlier than if we didn’t have our companies working together," Gilead Chief Executive Daniel O’Day told the Wall Street Journal in an interview.

Related Links: Merck & Co. Inc.Gilead Sciences Inc.
Breaking the News / JC